As LRPPRC is an emerging protein biomarker and a promising therapeutic target for the most lethal PP subtype of LUAD22, we hypothesized that T-96 could be a candidate drug for the treatment of lung adenocarcinoma. This evidence concerns the gene LRPPRC and lung adenocarcinoma.